$13.37
+0.06
(+0.45%)▲
1.72%
Downside
Day's Volatility :4.09%
Upside
2.41%
23.04%
Downside
52 Weeks Volatility :49.13%
Upside
33.91%
Period | Pliant Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 12.7% | 6.5% | 0.0% |
6 Months | -22.35% | 7.1% | 0.0% |
1 Year | -22.39% | 9.8% | 0.0% |
3 Years | -46.14% | 14.2% | -20.2% |
Market Capitalization | 776.4M |
Book Value | $7.25 |
Earnings Per Share (EPS) | -2.86 |
Wall Street Target Price | 41.82 |
Profit Margin | 0.0% |
Operating Margin TTM | -78404.03% |
Return On Assets TTM | -21.71% |
Return On Equity TTM | -34.17% |
Revenue TTM | 248.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 9.7M |
EBITDA | -192.5M |
Diluted Eps TTM | -2.86 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.4 |
EPS Estimate Next Year | -3.69 |
EPS Estimate Current Quarter | -0.77 |
EPS Estimate Next Quarter | -0.81 |
What analysts predicted
Upside of 212.79%
Sell
Neutral
Buy
Pliant Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Pliant Therapeutics Inc | 25.8% | -22.35% | -22.39% | -46.14% | -37.51% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Pliant Therapeutics Inc | NA | NA | NA | -3.4 | -0.34 | -0.22 | NA | 7.25 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Pliant Therapeutics Inc | Buy | $776.4M | -37.51% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Pliant Therapeutics Inc
Revenue is up for the last 2 quarters, 248.0K → 4.83M (in $), with an average increase of 94.9% per quarter
Netprofit is down for the last 2 quarters, -41.10M → -46.95M (in $), with an average decrease of 14.2% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 84.0%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 232.6%
Deep Track Capital, LP
BlackRock Inc
T. Rowe Price Associates, Inc.
FMR Inc
First Light Asset Management, LLC
Vanguard Group Inc
pliant therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. by harnessing the therapeutic potential of integrin biology and tgf-β modulation, pliant aims to prevent or even reverse fibrosis to address the needs of many patients. the company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. pliant’s co-founders include world-renowned researchers from university of california, san francisco (ucsf), who bring broad experience in fibrosis biology and small molecule chemistry. together, the pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
Organization | Pliant Therapeutics Inc |
Employees | 158 |
CEO | Dr. Bernard Coulie M.B.A., M.D., Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$13.37
+0.45%
Keyarch Acquisition Corp
$13.37
+0.45%
Connexa Sports Technologies Inc
$13.37
+0.45%
Us Value Etf
$13.37
+0.45%
First Wave Biopharma Inc
$13.37
+0.45%
Global X Msci Next Emerging
$13.37
+0.45%
Fat Projects Acquisition Corp
$13.37
+0.45%
Capital Link Global Fintech
$13.37
+0.45%
Applied Uv Inc
$13.37
+0.45%